Biophore receives sub-licence from MPP to manufacture and market Molnupiravir

The company has received DCGI regulatory license for the Indian market, applicable for both API as well as the finished product

Biophore India Pharmaceuticals has announced that it has received licence from Medicines Patent Pool (MPP) on behalf of MSD, to manufacture and market Molnupiravir API and finished product in capsule form. The development of the product is complete, and it is gearing up for launch based on this licence within the next one week. The licence received by Biophore enables the company to launch the product within India as well as export to 104 other countries around the world, the company notified via a statement.

It also said that for the Indian market, the company has informed that it has already received the relevant regulatory approvals from DCGI, and will be launching the product next week at one of the lowest prices currently in the market – Rs 1,500 for a pack of 40 capsules.

The statement further quoted Dr Jagadeesh Babu Rangisetty, CEO, Biophore, as saying, “…..During the earlier wave, we had scaled up and commercialised Favipiravir….We are also the largest Indian manufacturers of SBECD, a vital ingredient for Remdesivir injection manufacturing, and have also developed Nirmatrelvir, which is the active ingredient in the other US FDA-approved oral COVID antiviral. Similarly, we are committed to bring Molnupiravir to the market in the shortest time possible complying to all quality and regulatory requirements – all our products are manufactured in the US FDA approved facilities.”

Biophore India PharmaceuticalsCOVID-19 pillMedicines Patent PoolMerck Pharmamolnupiravir
Comments (0)
Add Comment